Meyka Pro banner
Bristol-Myers Squibb Company Ce

Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) AI-Powered Stock Analysis

See how Bristol-Myers Squibb Company Ce scores across key metrics like financial growth, valuation, and market position on the NYSE, using AI-driven evaluation.

CELG-RINYSE
HealthcareDrug Manufacturers - General
$0.10
$0.009(8.10%)
U.S. Market opens in 0h 48m

Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) AI-Powered Stock Analysis

See how Bristol-Myers Squibb Company Ce scores across key metrics like financial growth, valuation, and market position on the NYSE, using AI-driven evaluation.

Model Information

The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full Disclaimer

Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) Stock Overall Grade

Bristol-Myers Squibb Company Ce's grade for its NYSE listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.

Z

Grade Breakdown by Metric

See how each financial and market factor contributes to Bristol-Myers Squibb Company Ce's overall NYSE stock rating.

Forecast

C+

Score

55/100

Financial Growth

C

Score

40/100

Fundamental Growth

B+

Score

79/100

Key Ratios

C

Score

42/100

Sector Comparison

B+

Score

75/100

Industry Comparison

C+

Score

50/100

S&P 500 Benchmark

A+

Score

99/100

Analyst Consensus

C+

Score

50/100

Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) AI-Powered Stock Analysis

On the NYSE, CELG-RI demonstrates Normal performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (79/100, B+) highlight its stability, while Key Ratios (42/100, C) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (99/100, A+), the NYSE-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.

(NYSE: CELG-RI) Component Analysis Explained

Understand the key factors behind each Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) stock grade, including financials, comparisons, and forecasts.

Frequently Asked Questions